GTB-5550
2025LS049
Phase 1 small_molecule active
Quick answer
GTB-5550 for Tri-specific Killer Engager is a Phase 1 program (small_molecule) at GT Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GT Biopharma
- Indication
- Tri-specific Killer Engager
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active